Delcath Systems Inc (DCTH) Stock Price, Quote & News

Company Profile

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal...

Industry: Medical Devices

Sector: Healthcare

Phone: 212 489 2100

Fax: 212 489 2102

Website: www.delcath.com

Address:

566 Queensbury Avenue, New York, United States

RegulatoryPro Feb. 18 at 4:26 PM

$DCTH Delcath Systems develops targeted liver cancer therapies. Commercial adoption is early-stage. Regulatory execution defines value.

0 · Reply

DragonAlgo Feb. 18 at 2:54 PM

🐉 $DCTH CALL — DragonAlgo® Signal Contract: DCTH CALL Expiry: 2026-02-20 | Strike: $10.00 | Type: CALL Option Plan (premium): Entry: $0.06 Stop: $0.04 TP1: $0.08 TP2: $0.10 TP3: $0.14 🔗 https://dragonalgo.com

0 · Reply

alexpitti Feb. 16 at 4:18 PM

$DCTH I guess some sell side event had delcath invited and they said they are publishing the CHOPIN results in early march which is obviously in a few weeks

2 · Reply

xcdvfxcvnbxxvsd Feb. 16 at 7:06 AM

$DCTH I read from X (again) that there were interesting info on the Eye on CHOPIN Study Insights & Personalizing Treatment in MUM last Saturday... i.e. Chopin results getting published early March. https://x.com/Medtechgur23109/status/2022801778249449840 The recording of the event should be available in the Cure in Sight YouTube channel in couple of weeks.

1 · Reply

alexpitti Feb. 15 at 7:13 PM

$DCTH recent price action actually got me fired. which is crazy because these are just random noise. the business should be in great shape in 2026

1 · Reply

donkeykongreturns Feb. 15 at 4:39 PM

$DCTH $ARDX Interesting read for anyone interested in the future of clinical trials and the impact it could have on drug companies and related support organizations

1 · Reply

S144 Feb. 14 at 7:50 PM

$DCTH Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call: February 26, 2026 https://investors.delcath.com/news-releases/news-release-details/delcath-systems-host-fourth-quarter-and-full-year-2025-earnings We already know what revenue will be in Q4 - nothing exciting as it will be similar to Q3. So the key thing will be the guidance for 2026. One problem is: revenue in second half of 2025 stopped growing. So the question is: was it a temporary issue and will the growth resume in 2026 ? The key to revenue growth is increase in the number of treatment centers. At the end of Q3 they had 25 treatment centers. The company expects to operate "26 to 28 active treating centers by the end of 2025 and 40 centers by the end of next year." So the company expects significant expansion: 48% increase of treatment centers. I think that should be good predictive indicator of revenue growth. Revenue could grow by similar number.

1 · Reply

alexpitti Feb. 14 at 12:05 AM

Delcath is expected to do $113 million in 2026 sales. since we already know their q4 results, the only question is if they guide for somewhere above this. the main negative is the results from the CHOPIN study haven't come out yet. on the positive side, Delcath management may have noticed increased usage at some centers without it being published. the hope is they guide for $110 to $120 million in sales which is slightly above estimates $DCTH

1 · Reply

Quantumup Feb. 13 at 3:32 PM

Craig-Hallum🏁 $CMPX ~argues Tovecimig already met the ORR 1° of a Ph3 2L BTC study/ PFS/OS data is expected in Mar—expects these data to support a pot '27 comm launch in 2L BTC (models a $1B peak oppy)—+sees sig⬆️pot from early-stage pipeline. $AZN $ BMY $BNTX $DCTH MRK Here's what else Craig-Hallum said in its initiation report: https://x.com/Quantumup1/status/2022332075974488090?s=20

0 · Reply

OfficialStocktwitsUser Feb. 13 at 3:27 AM

$DCTH RSI: 31.97, MACD: -0.1861 Vol: 0.49, MA20: 9.99, MA50: 10.06 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call

Jan 27, 2026, 8:05 AM EST - 22 days ago

Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 21, 2026, 4:01 PM EST - 27 days ago

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 13, 2026, 12:22 PM EST - 5 weeks ago

Delcath Systems: Stabilizing Fundamentals Justify A Rating Upgrade

Jan 9, 2026, 8:05 AM EST - 5 weeks ago

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

Dec 31, 2025, 8:00 AM EST - 7 weeks ago

Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma

Dec 3, 2025, 4:01 PM EST - 2 months ago

Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma

Nov 20, 2025, 4:01 PM EST - 3 months ago

Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program

Nov 18, 2025, 8:00 AM EST - 3 months ago

Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma

Nov 13, 2025, 8:30 AM EST - 3 months ago

Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients

Nov 6, 2025, 4:01 PM EST - 3 months ago

Delcath Systems to Participate in Upcoming Investor Conferences

Nov 6, 2025, 2:15 PM EST - 3 months ago

Delcath: Temporary Headwinds Are No Cause For Concern

Nov 4, 2025, 5:16 PM EST - 3 months ago

Delcath Systems, Inc. (DCTH) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 8:00 AM EST - 3 months ago

Delcath Systems Reports Third Quarter 2025 Results and Business Highlights

Oct 21, 2025, 8:30 AM EDT - 4 months ago

Delcath Systems to Host Third Quarter 2025 Earnings Call

Oct 20, 2025, 5:05 PM EDT - 4 months ago

Delcath Systems, Inc. (DCTH) Discusses CHOPIN Trial Results and Preliminary Q3 Financials Transcript

Oct 20, 2025, 3:06 PM EDT - 4 months ago

Delcath: Large Upside With Limited Downside Risk

Oct 18, 2025, 4:15 PM EDT - 4 months ago

Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results

Oct 18, 2025, 4:13 PM EDT - 4 months ago

Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint

Sep 22, 2025, 4:01 PM EDT - 5 months ago

Delcath Systems Announces Investigator-Initiated CHOPIN Phase 2 Trial Presentation at ESMO 2025 Congress

Aug 19, 2025, 8:30 AM EDT - 6 months ago

Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

Aug 6, 2025, 3:06 PM EDT - 6 months ago

Delcath Systems, Inc. (DCTH) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 8:00 AM EDT - 7 months ago

Delcath Systems Reports Second Quarter 2025 Results and Business Highlights

Jul 29, 2025, 4:01 PM EDT - 7 months ago

Delcath Systems to Participate at the Canaccord Genuity 45th Annual Growth Conference

Jul 23, 2025, 4:01 PM EDT - 7 months ago

Delcath Systems to Host Second Quarter 2025 Earnings Call

Jun 12, 2025, 8:36 AM EDT - 8 months ago

Delcath Systems: Growing Fast, But Business Model Is Fragile

May 22, 2025, 7:00 AM EDT - 9 months ago

Delcath Systems Issues Full Year 2025 Guidance

May 18, 2025, 8:25 AM EDT - 9 months ago

Delcath Systems: Q1 Earnings Show A Growth Spurt And Switch To Execution

May 15, 2025, 4:30 PM EDT - 9 months ago

Delcath Systems to Participate at the Craig-Hallum 22nd Annual Investor Conference

May 9, 2025, 5:30 PM EDT - 10 months ago

Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 8, 2025, 10:55 AM EDT - 10 months ago

Delcath Systems, Inc. (DCTH) Q1 2025 Earnings Call Transcript

May 8, 2025, 7:30 AM EDT - 10 months ago

Delcath Systems Reports First Quarter 2025 Results and Business Highlights

Apr 28, 2025, 8:30 AM EDT - 10 months ago

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

Apr 24, 2025, 4:01 PM EDT - 10 months ago

Delcath Systems to Host First Quarter 2025 Earnings Call

Apr 9, 2025, 5:00 PM EDT - 11 months ago

Delcath Systems Announces Publication of Comparative Analysis from Randomized Portion of FOCUS Study in Metastatic Uveal Melanoma

Apr 2, 2025, 11:49 AM EDT - 11 months ago

Hospitals Experience FOMO In Adopting Delcath's PHP Treatment

Mar 24, 2025, 4:01 PM EDT - 11 months ago

Delcath Systems to Participate at the Canaccord Genuity Horizons in Oncology Virtual Conference

Mar 14, 2025, 4:01 PM EDT - 1 year ago

Delcath Systems, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mar 6, 2025, 2:17 PM EST - 1 year ago

Delcath Systems, Inc. (DCTH) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 8:00 AM EST - 1 year ago

Delcath Systems Reports Fourth Quarter and Full Year 2024 Results

Feb 20, 2025, 8:30 AM EST - 1 year ago

Delcath Systems to Host Fourth Quarter and Full Year 2024 Earnings Call

Feb 14, 2025, 8:30 AM EST - 1 year ago

Delcath Systems Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines for the Treatment of Metastatic Uveal Melanoma

Jan 30, 2025, 7:06 PM EST - 1 year ago

Biotech walks a 'tightrope' amid unclear funding, regulations

ELVN IBB

Jan 28, 2025, 4:01 PM EST - 1 year ago

Delcath Systems to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 13, 2025, 8:00 AM EST - 1 year ago

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

Jan 3, 2025, 4:01 PM EST - 1 year ago

Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 30, 2024, 8:00 AM EST - 1 year ago

Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises

Dec 2, 2024, 8:30 AM EST - 1 year ago

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

Nov 20, 2024, 7:50 AM EST - 1 year ago

Delcath Begins Platform Expansion With Two Phase 2 Trials

Nov 18, 2024, 7:09 AM EST - 1 year ago

Delcath Systems: Q3 Earnings Reveal HEPZATO KIT And CHEMOSAT Growth

RegulatoryPro Feb. 18 at 4:26 PM

$DCTH Delcath Systems develops targeted liver cancer therapies. Commercial adoption is early-stage. Regulatory execution defines value.

0 · Reply

DragonAlgo Feb. 18 at 2:54 PM

0 · Reply

alexpitti Feb. 16 at 4:18 PM

$DCTH I guess some sell side event had delcath invited and they said they are publishing the CHOPIN results in early march which is obviously in a few weeks

2 · Reply

xcdvfxcvnbxxvsd Feb. 16 at 7:06 AM

1 · Reply

alexpitti Feb. 15 at 7:13 PM

$DCTH recent price action actually got me fired. which is crazy because these are just random noise. the business should be in great shape in 2026

1 · Reply

donkeykongreturns Feb. 15 at 4:39 PM

$DCTH $ARDX Interesting read for anyone interested in the future of clinical trials and the impact it could have on drug companies and related support organizations

1 · Reply

S144 Feb. 14 at 7:50 PM

1 · Reply

alexpitti Feb. 14 at 12:05 AM

1 · Reply

Quantumup Feb. 13 at 3:32 PM

0 · Reply

OfficialStocktwitsUser Feb. 13 at 3:27 AM

0 · Reply

actuallysam Feb. 12 at 4:37 PM

$DCTH The stock price suggests delcath is slow on revenue growth. Either it is slow or it is not. Which is it?

0 · Reply

brunoq14 Feb. 12 at 1:14 PM

$DCTH Conference Call Q4 February 26.

0 · Reply

forprofit12 Feb. 11 at 7:09 PM

$DCTH one of those companies where management seems to be non-existent. Radio silence

2 · Reply

alexpitti Feb. 11 at 3:31 PM

$DCTH sofware stock again!

1 · Reply

alexpitti Feb. 10 at 3:47 PM

$DCTH fell below 9 last week because google missed earnings estimates. Thank god people realized Delcath is not a software stock lol

1 · Reply

xcdvfxcvnbxxvsd Feb. 10 at 12:08 PM

$DCTH Another interesting catch from the video I posted earlier from X. She posted the same video on tiktok and there are interesting comments in the video like the ones below. The tiktok version with comments is here: https://www.tiktok.com/@its.biancamichelle/video/7597966496400198967

0 · Reply

TabulaRasa13 Feb. 8 at 8:29 PM

$DCTH are there any late stage therapies in trials that would cause a competitive threat to DCTH? Thinking long term terminal value risk as I can’t understand why this is so cheap

2 · Reply

brunoq14 Feb. 7 at 11:06 AM

$DCTH Market Edge Second Opinion, since 01/09/2026 rated LONG Reuters Average Rating since 02/05/2026, OUTPERFORM

0 · Reply

xcdvfxcvnbxxvsd Feb. 7 at 7:23 AM

$DCTH the last 20 seconds is interesting :) https://www.facebook.com/reel/1213401743589157

2 · Reply

Playthegame06 Feb. 6 at 1:20 AM

$DCTH I’m hoping DCTH advisors are telling them to start buying shares to support the price!!

1 · Reply

BillionerOfKing Feb. 5 at 11:46 PM

$DCTH Current Stock Price: $8.94 Contracts to trade: $10.0 DCTH Feb 20 2026 Call Entry: $0.05 Exit: $0.08 ROI: 61% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

AlxNT Feb. 5 at 11:32 PM

$DCTH I don't see what this company has to do with AI and BTC bubble. Mr Market is crazy 😅

1 · Reply

Market Cap	328.77M
Revenue (ttm)	37.21M
Net Income (ttm)	-26.39M
EPS (ttm)	N/A
PE Ratio	53.65
Forward PE	15.72
Profit Margin	-70.92%
Debt to Equity Ratio	0.00

Volume	87,786
Avg Vol	501,086
Day's Range	N/A - N/A
Shares Out	35.31M
Stochastic %K	36%
Beta	0.37
Analysts	Strong Sell
Price Target	$23.50